TAU antibody, Tau (Phospho-Ser235) Antibody, Rabbit Polyclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

Tau (Phospho-Ser235) Antibody, Rabbit Polyclonal Antibody

Catalog Number: 18-785-210449

Buy TAU antibody -

Size:

Related Product Names:

- TAU antibody; TAU; MAPTL; MTBT1; TAU; Tau (Phospho-Ser235)
- Neurofibrillary tangle protein; Paired helical filament-tau; PHF-tau; Microtubule-associated protein tau

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: TAU	Gene Name Synonym: MAPTL; MTBT1; TAU
Gi #: N/A	NCBI Acc #: N/A	Swiss Prot Acc #: P10636
Length (aa): N/A	Mol. Weight (Da): 78878	Chrom Location: N/A

Binding Site: Ser235

WB Dilution: 500~1000

IHC Dilution: 50~100

Source/Host: Rabbit

Purity/Purification: Affinity Purified

Clonality: Polyclonal

Crossreactivity: Human, Mouse, Rat

Format: In PBS, 0.02% sodium azide and 50% glycerol.

Storage: 4C for short term (weeks) and -20C for long term. Avoid frequent freeze and thaw.

Stability: 1 year at -20C

Shipping: Products may be shipped on ice pack or dry ice.

APPLICATIONS for TAU ANTIBODY:

WB: Tested

TESTING: (secondary reagents and protocols )

Western Blot ( anti-TAU )

TAU antibody tern B image
TAU

TAU ANTIBODY TARGET DESCRIPTION:

Synonym Names for TAU antibody: TAU; MAPTL; MTBT1; TAU; Neurofibrillary tangle protein; Paired helical filament-tau; PHF-tau; Microtubule-associated protein tau

Function: Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

Subunit: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.

Subcellular Location: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

Tissue Specificity: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.

Developmental Stage: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain whereas three-repeat (type I) tau is found in both adult and fetal brain.

Domain: The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.

Ptm: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.

Ptm: Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.

Ptm: Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic posttranslational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.

Disease: In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).

Disease: Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also historically termed Pick disease. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.

Disease: Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia.

Disease: Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.

Disease: Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson-Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Disease: Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.

Similarity: Contains 4 Tau/MAP repeats.

Tau (Phospho-Ser235) reacts with human, mouse, rat.

OMIM: 157140; gene+phenotype. [NCBI / EBI]
172700; phenotype. [NCBI / EBI]
260540; phenotype. [NCBI / EBI]
600274; phenotype. [NCBI / EBI]
601104; phenotype. [NCBI / EBI]
607485; phenotype. [NCBI / EBI]

Pathways:
KEGG pathway: Alzheimer's disease 05010
KEGG pathway: MAPK signaling pathway 04010
KEGG pathway: Neurodegenerative Disorders 01510

Products similar to TAU antibody:

IgG

Tau, IgG

Tau [TAU 2] (Biotin), IgG

p42IP4 [P421], IgG

Tau, IgG

Tau phospho S409, IgG

Peptide

Tau (Phospho-Ser404) Antibody Blocking Peptide, Peptide

Tau (Phospho-Ser214) Antibody Blocking Peptide, Peptide

Tau (Phospho-Ser235) Antibody Blocking Peptide, Peptide

Tau (Phospho-Ser262) Antibody Blocking Peptide, Peptide

Tau (Phospho-Thr205) Antibody Blocking Peptide, Peptide

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

BACKGROUND REFERENCES for TAU ANTIBODY:

Background references for antibody target are not specific to GenWay products

[1] Goedert M., Wischik C., Crowther R., Walker J., Klug A.
     Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.
[2] Goedert M., Spillantini M.G., Potier M.-C., Ulrich J., Crowther R.A.
     Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.
[3] Lee G., Neve R.L., Kosik K.S.
     The microtubule binding domain of tau protein.
[4] Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A.
     Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.
[5] Andreadis A., Brown W.M., Kosik K.S.
     Structure and novel exons of the human tau gene.
[6] Chun J., Kwon T., Lee E.-J., Hyun S.-H., Kang S.S.
     Cloning of tau-related genes.
[7] Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., et al.
     Cloning of human full-length CDSs in BD Creator(TM) system donor vector.
[8] Hasegawa M., Morishima-Kawashima M., Takio K., Suzuki M., Titani K., Ihara Y.
     Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain.
[9] Han J., Zhang J., Dong X.-P.
     Molecular interactions of recombinant neural protein tau with recombinant and native PrP proteins in vitro.
[10] Cripps D., Thomas S.N., Jeng Y., Yang F., Davies P., Yang A.J.
     Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: TAU antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of TAU antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about TAU antibody, all related information, articles, resources about TAU antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved